[HTML][HTML] Reduction of BCR-ABL transcript levels at 6, 12, and 18 months (mo) correlates with long-term outcomes on imatinib (IM) at 72 mo: an analysis from the …
TP Hughes, A Hochhaus, S Branford, MC Müller… - Blood, 2008 - Elsevier
Background: An exploratory endpoint of the IRIS trial was measurement of BCR-ABL
transcripts over time and its correlation with long-term outcomes. BCR-ABL measured by …
transcripts over time and its correlation with long-term outcomes. BCR-ABL measured by …
[引用][C] Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the …
TP Hughes, A Hochhaus, S Branford… - Blood: 50th Annual …, 2008 - eprints.ncl.ac.uk
Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term
Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of …
Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of …
Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the …
TP Hughes, A Hochhaus, S Branford, MC Müller… - 2008 - ashpublications.org
Background: An exploratory endpoint of the IRIS trial was measurement of BCR-ABL
transcripts over time and its correlation with long-term outcomes. BCR-ABL measured by …
transcripts over time and its correlation with long-term outcomes. BCR-ABL measured by …
[引用][C] Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: an Analysis from the …
T HUGHES - Blood, 2008 - cir.nii.ac.jp
Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term
Outcomes on Imatinib (IM) at 72 Mo : an Analysis from the International Randomized Study of …
Outcomes on Imatinib (IM) at 72 Mo : an Analysis from the International Randomized Study of …
[引用][C] Reduction of BCR-ABL transcript levels at 6, 12, and 18 months (mo) correlates with long-term outcomes on imatinib (IM) at 72 mo: An analysis from the …
H TP - Blood, 2008 - cir.nii.ac.jp
Reduction of BCR-ABL transcript levels at 6, 12, and 18 months (mo) correlates with long-term
outcomes on imatinib (IM) at 72 mo : An analysis from the International Randomized Study of …
outcomes on imatinib (IM) at 72 mo : An analysis from the International Randomized Study of …